Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Enrique Martinez-Rodriguez

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|February 25, 2025
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?Silvia Susin-Calle, Jose Enrique Martinez-Rodriguez, Elvira Munteis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 31, 2007
Cerebrospinal fluid hypocretin-1 levels in multiple system atrophyJose Enrique Martinez-Rodriguez, Klaus Seppi, Adriana Cardozo, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 26, 2015
Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trialPablo Villoslada, Alex Rovira, Xavier Montalban, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|February 25, 2025
Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?Silvia Susin-Calle, Jose Enrique Martinez-Rodriguez, Elvira Munteis, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 31, 2007
Cerebrospinal fluid hypocretin-1 levels in multiple system atrophyJose Enrique Martinez-Rodriguez, Klaus Seppi, Adriana Cardozo, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 26, 2015
Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trialPablo Villoslada, Alex Rovira, Xavier Montalban, et al.
Pageof 1